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Abstract
Serological proteome analysis (SERPA) combines classical proteomic technology with
effective separation of cellular protein extracts on two-dimensional gel electrophoresis,
western blotting, and identification of the antigenic spot of interest by mass spectrometry. A
critical point is related to the antigenic target characterization by mass spectrometry, which
depends on the accuracy of the matching of antigenic reactivities on the protein spots dur-
ing the 2D immunoproteomic procedures. The superimposition, based essentially on visual
criteria of antigenic and protein spots, remains the major limitation of SERPA. The introduc-
tion of fluorescent dyes in proteomic strategies, commonly known as 2D-DIGE (differential
in-gel electrophoresis), has boosted the qualitative capabilities of 2D electrophoresis.
Based on this 2D-DIGE strategy, we have improved the conventional SERPA by developing
a new and entirely fluorescence-based bi-dimensional immunoproteomic (FBIP) analysis,
performed with three fluorescent dyes. To optimize the alignment of the different antigenic
maps, we introduced a landmark map composed of a combination of specific antibodies.
This methodological development allows simultaneous revelation of the antigenic, landmark
and proteomic maps on each immunoblot. A computer-assisted process using commer-
cially available software automatically leads to the superimposition of the different maps,
ensuring accurate localization of antigenic spots of interest.
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Introduction
Immunofluorescence, enzymatic and immunoprecipitation assays have been widely used for
the identification of biomarkers in various diseases. These conventional methods are frequently
based on immunoassays performed with limited antigenic targets, the choice of which has been
driven by a supposedly well known pathophysiological rationale. Advances in proteomic meth-
odologies (in vitro gene expression, 2D electrophoresis (2DE) and mass spectrometry) have
allowed the emergence of standardized broad spectrum analysis methods such as serological
analysis of recombinant tumor cDNA expression libraries (SEREX) and serological proteomic
analysis (SERPA). These approaches have been developed to overcome the limitations of con-
ventional methods. Based on a “without any a priori” strategy, they offer a simultaneous analy-
sis of a wide range of reactivities, which surpasses the physiopathogenic hypotheses and offers
an integrative interpretation of results.
SERPA, also called PROTEOMEX (an abbreviation of proteomics and SEREX) or SPEAR
(serological and proteomic evaluation of antibody responses) [1], is a popular method that
is judged to be reproducible and broadly applicable. It consists of combined proteomic
approaches for the separation of proteins of interest and the serological screening of human
serum antibodies. In contrast to SEREX, SERPA offers the advantage of considering the post-
translational modifications in the natural context of protein expression. SERPA has been
extensively used in different conditions and animal models such as allergic [2] and autoim-
mune [3–6] diseases but also in other conditions: cancerology [7–9], metabolism [10], toxicol-
ogy [11] and infectiology [12–18]. However, after a decade of using SERPA, some
methodological problems have emerged and must be emphasized. As observed for the proteo-
mic approach [19], data obtained by SERPA have revealed the identification of redundant bio-
markers in very different and unrelated disease conditions. A ‘hit-parade’ of the five most
frequently reported targets of specific reactivities by SERPA in humans comprises: anti-eno-
lase, anti-isomerase [4,6,8,20–32], anti-heat shock proteins [4,6,8,23–29,33–37], anti-heteroge-
neous nuclear ribonucleoprotein [8,28–31,38–41] and anti-peroxiredoxin [8,25–29,32,42]
families. For example, specific anti-α-enolase reactivity has been described both in autoim-
mune diseases (multiple sclerosis [4], systemic sclerosis [29,37], autoimmune hepatitis
[31,43,44], type 1 diabetes [32], rheumatoid arthritis [45,46], celiac disease [47] and Behçet’s
disease [48,49]) and in different types of cancer (breast cancer [8,34], lung cancer [25,26], colo-
rectal cancer [27], melanoma [41] and leukemia [50]). Only in rheumatoid arthritis has the
specificity of anti α-enolase been confirmed, linked to the deimination of the target [46]. Such
redundant identification could be explained, at least in part, by the interpretation biases linked
to the superimposition of images of 2-DE immunoblots and gels. While these issues have been
resolved in proteomics by differential in-gel electrophoresis (2D-DIGE) [51], these steps
remain a major limitation in SERPA [52] even if different strategies have been proposed to cir-
cumvent them. These approaches are based either on the generation of a map of fixed bench-
marks that offers additional visual anchors (so-called “landmark map” [4]) or the revelation of
the proteomic map onto each immunoblot [34,36,53–55]. Even if they help final superimposi-
tion of the antigenic and the proteomic maps to target the protein spot to excise, these
approaches still remain insufficient due to the persistence of an operator-dependent step to
superimpose the different maps.
We propose here a new strategy, named ‘Fluorescence-based bidimensional immunoproteo-
mic’ (FBIP) approach, derived from the 2D-DIGE procedure to ensure the accurate superim-
position of the different maps. This methodology uses fluorescent probes to simultaneously
reveal three maps on each immunoblot: the antigenic, the landmark and the proteomic maps.
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The superimposition stage now becomes an automated step based on a computer-assisted pro-
cess using commercially available software.
Materials and Methods
Serological Antibodies
In order to illustrate our procedure, we analyzed the self IgG antibody responses with sera
from 2 patients suffering from systemic lupus erythematosus. All patients gave their written
informed consent and the study was approved by the local ethics committee (DC-2008-642;
CHRU, Lille 2 University, France).
Commercial Antibodies
Mouse monoclonal antibodies (mAbs) recognizing triosephosphate isomerase (TPIS, catalog
reference TPI, H-11), glyceraldehyde phosphate dehydrogenase (GAPDH, catalog referenceA-
3), β-actin (ACTB, catalog reference ACTBD11B7), α-enolase (ENOA, catalog reference A-5),
heat shock 70 kDa protein (HSP71, catalog reference 3A3) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA) were used as a benchmark on the 2D immunoblots, providing anchors
for the inter-assay alignment by generating a landmark map. Their localization on different
proteomic maps has been extensively described (http://www.uniprot.org). The selection of
these benchmarks was based on both their large pI and MW distributions on the proteomic
map.
Cell Cultures and Treatments
The human epithelial line cell HEp-2 from the American collection of cell cultures (ATCC
CCL-23) was used for the experiments. HEp-2 cells were cultured in minimum essential
medium (MEM) supplemented with 2mM L-glutamine, penicillin/streptomycin (50 units/
mL), 1% sodium pyruvate, 1% non-essential amino acids and containing 10% (v/v) heat-inacti-
vated fetal calf serum (FCS) (MEM-10% FCS) (Life technologies, Carlsbad, CA, USA). Cells
were maintained at 37°C in a saturated humidity atmosphere containing 95% air and 5% CO2
in 75-cm2 flasks. For cell culture experiments, HEp-2 cells were detached by means of Trypsin/
EDTA solution (Life technologies), re-suspended in MEM-10% FCS. After centrifugation at
1500 rpm for 10 min, numeration was performed using Scepter (Merck Millipore, Darmstadt,
Germany), and cells were washed in PBS and then seeded at a concentration of 2x106 cells per
75 cm² flask.
Two-Dimensional Electrophoresis (2DE)
Protein extraction. The cell homogenization was performed as previously described [56].
Briefly, 5x106 cells were homogenized in lysis buffer (8M urea/2M thiourea (GE Healthcare,
Uppsala, Sweden), 4% CHAPS (Sigma Aldrich, Saint Louis, MO, USA), 50 mMDTT, anti-pro-
tease cocktail (Roche Diagnostics, Mannheim, Germany)) before protein precipitation using
the 2D clean-up kit (GE Healthcare). The supernatant was removed and the pellet was sus-
pended in 250 μl of sample buffer (8M urea/2M thiourea, 4% CHAPS). The protein concentra-
tion was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA, USA).
Protein labeling. This step was exclusively used for the FBIP approach. Fifty micrograms
per strip of HEp-2 extract protein were labeled with 400 pmol Cy3 dye (GE Healthcare),
according the manufacturer’s instructions. Cy5 dye labeling was used when a post-staining
step with Deep Purple (DP, GE Healthcare) was performed.
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Isoelectrofocusing. Five hundred micrograms of proteins (of which 50 μg was labeled for
FBIP approach) were resuspended in 350 μl of rehydration buffer composed by 8M urea/2M
thiourea, 2% CHAPS, DeStreak Reagent (15 mg/ml, GE Healthcare) and ampholytes (1% IPG
buffer, GE Healthcare). Sample loading for the first dimension was performed by passive in-gel
rehydration. Proteins were first separated according to their isoelectric point (pI) along a non-
linear (NL) immobilized pH gradient (IPG) strip (pH 3–11NL, 18 cm long; GE Healthcare)
using the IPGphor III apparatus (GE Healthcare) for a total of 40,000 V.h.
SDS-PAGE electrophoresis. After focusing, the IPG strips were equilibrated for 15 min in
a buffer 1 containing 6 M urea, 2% SDS, 30% glycerol, 50 mM Tris/HCl pH 8.6 and 1% DTT,
and then for 15 min in buffer 2, in which the DTT in buffer 1 was replaced by 4.7% iodoaceta-
mide. For the second dimension, equilibrated strips were loaded onto homemade 8–18% gradi-
ent polyacrylamide gels and overlaid with agarose solution (0.5% low-melting agarose and a
trace amount of bromophenol blue). Electrophoresis was performed for 13–14 h in EttanDalt
Six (GE Healthcare) with power limited to 3 W per gel. Among the 6 performed gels, one was
used for Coomassie colloidal blue (CCB) staining.
Blotting
Gels were blotted onto Hybond-ECL membranes (GE Healhtcare) using a “semi-dry” protocol
(0.8 mA per cm²) and a discontinuous buffer system [57] for 2 hours.
Immunoblotting
SERPA. Membranes were saturated with 5% non-fat dried milk. Western blotting was car-
ried out with total sera (1/100). One membrane per patient’s serum has to be used in order to
analyze the related antigenic map. For each study, one membrane is dedicated for the landmark
map using a pool of commercial mAbs (anti-HSP71, 1/1,500; anti-ENOA, 1/5,000;anti-ACTB,
1/750; anti-G3P, 1/750; anti-TPIS, 1/200,000). Sera and commercial mAbs were diluted in Tris
buffer saline (TBS: 100 mM Tris, pH 8.0; 0.3 M NaCl) containing 0.5% Tween20 (w/v) and 5%
non-fat dried milk. After incubation overnight at 4°C, each antigenic map was revealed with an
anti-human IgG horseradish peroxidase (HRP)-conjugated antibody 1/5,000 (Sigma Aldrich)
and the landmark was revealed by HRP-conjugated anti-mouse IgG antibody 1/5,000 (Sigma
Aldrich). All fluorograms were prepared using an enhanced chemiluminescence kit (GE
Healthcare).
FBIP approach. After the step involving saturation of the membranes by 5% non-fat dried
milk, the FBIP procedure allows one step co-hybridization of human serum defining the anti-
genic map and commercial antibodies defining the landmark map. After incubation overnight
at 4°C, serum IgG reactivities were revealed with an anti-human IgG HRP-conjugated antibody
1/5,000 (Sigma Aldrich), and commercial mAbs were revealed using a donkey anti-mouse
Alexa Fluor (AF) 647-conjugated Ab (Life Technologies). The peroxidase activity was revealed
using an enhanced chemifluorescence kit (ECL PLUS, Pierce Biotechnology, Thermo Scientific,
Sunnyvale, CA, USA). The 3 maps of each immunoblotted membrane were read simulta-
neously on a Typhoon 9400 scanner (GE Healthcare) using 3 coupled excitation and emission
wavelengths: 532/580, 633/670, 488/520 for the proteomic (Cy3), landmark (AF647) and anti-
genic (ECL PLUS) maps, respectively. To take into account the potential MW shift related to
the dye labeling, we performed a complementary coloration of the proteomic map by DP.
Image Analysis Procedures
SERPA. The landmark and antigenic maps produced by the different 2D immunoblotting
procedures were superimposed using visual parameters by zonal translation. The landmark
New Immunoproteomic Approach for Autoantibodies Screening
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map helped with superimposing the serum immune patterns on the CCB-stained proteomic
map.
FBIP approach. The three 2D immunoblot maps simultaneously revealed by the Typhoon
9400 scanner were visualized immediately after capture with ImageQuant TL software (GE
Healthcare). Multichannel revelation in the 3 fluorescent wavelengths allowed direct, operator-
independent superimposition of both the antigenic and landmark maps on the proteomic map.
This step constituted the “intra-assay alignment” step. Next, Progenesis SameSpots software
(Totallab, Newcastle upon Tyne, England) was used for the process of inter-assay alignment
between the different antigenic maps. Based on the 2D-DIGE alignment process, the proteomic
maps used as internal standard were first aligned using correction vectors proposed by Progen-
esis SameSpots. After validation, the correction vectors defined for each proteomic map were
automatically applied to each antigenic and landmark map associated with its own proteomic
map. By comparing the landmark maps generated on each 2D immunoblot we were able to
refine the strict superimposition of the different proteomic maps. This procedure, using a spot-
by-spot approach, comparing both in-between serum reactivity and landmark map and serum
profiles revealed whether or not they shared antibody reactivities.
In-Gel Digestion and LTQ-ORBITRAP-Velos MS Analysis
MS protein identification procedures are detailed in Supporting Information (S1 Appendix).
Briefly, selected spots on the CCB-stained gel were manually excised (OneTouch 2D gel
spot picker, Gel Company, San Francisco, CA, USA) and placed in a 96-well microtiter plate
and conserved at -20°C. In-gel digestion and sample preparation were performed using the
Freedom Evo 100 automation system (Tecan, Männedorf, Switzerland). Digest peptides were
separated on a C18 nanochromatography column (RSLC Dionex, Thermo Scientific) directly
coupled to a mass spectrometer (LTQ-OrbitrapVelos, Thermo Scientific). Using peak lists of
peptide fragmentation fingerprint (PFF) and Proteome Discoverer 1.3 software (ThermoScien-
tific) led to the identification of protein by querying the MASCOT (MatrixScience) search
engine.
The global experimental design of FBIP approach is illustrated in Supporting Information
(S1 Fig).
Results
Targeting of Antigenic Spots using Chemiluminescence Based Bi-
Dimensional Immunoproteomic Approach: results and limits
SERPA is based on the comparison of multiple images derived from distinct hybridizations
obtained from different 2D immunoblotting procedures (Fig 1). In order to illustrate this
procedure, we used selected sera from 2 patients suffering from an autoimmune disease. To
facilitate the superimposition of these different antigenic maps (Fig 1A), we used a mix of com-
mercially available monoclonal Abs directed against proteins (ACTB, HSP71, ENOA, G3P and
TPIS) widely distributed in cellular extracts as for instance in HEp-2 cell line (Fig 1B). These
commercial mAbs defined an antigenic landmark and were used as anchors to enable spot
matching between the 2D immunoblots (Fig 1A) and the CCB proteomic map (Fig 1C).
Despite using this landmark map, we identified several limitations associated with this pro-
cedure. The first limitation was related to distortion of the final images (Fig 1A and 1C). The
distortions are linked to the electrophoresis separation, as illustrated by differences in the dis-
tribution of the molecular weight standards and spots between the images. As shown in Fig 1A,
the difference between the relative mobility of HSP71 and G3P spots was measured at 3.6 cm
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and at 3.3 cm on the antigenic maps respectively revealed with the serum 1 and 2. Moreover,
the immunoblotting and staining procedures induced size modifications of the images, at a
mean 19x17 cm and 26x22cm (length x height), respectively. On the proteomic map, the
relative mobility of HSP71 and G3P spots was measured at 5.3 cm (Fig 1C). Secondly the
serological hybridizations (Fig 1A) showed heterogeneous patterns containing from 10 to 300
antigenic spots, whereas CCB stained gel (Fig 1C) showed more than 1,000 protein spots dis-
tributed in the same ranges of pI and MW. Thirdly, we observed a strong heterogeneity of anti-
genic patterns between themselves (Fig 1A sera 1 and 2). In a particular region of the antigenic
maps obtained (yellow area), we numbered 192 and 78 spots of reactivity with sera 1 and 2
respectively. Fourthly, the aspects of the antigenic spot could be visually different between
them (HSP71, ENOA and G3P areas, Fig 1A, serum 1 and 2 & Fig 1B) and also with its own
protein counterpart on the CCB gel (Fig 1C). Fifthly, due to the weak sensitivity of the CCB
staining of the protein spots, each antigenic spot could not have its counterpart in the stained
gel (red area, Fig 1A serum 2 and Fig 1C).
Development of a NewMethod of SERPA using a Fluorescence-Based
Bi-Dimensional Immunoproteomic approach (FBIP)
To normalize the superimposition procedure for the different antigenic maps, we used a cya-
nine-labeled proteomic map, which revealed the protein spots in the immunoblots. This per-
manently labeled proteomic map was repeated on every membrane in order to be revealed
Fig 1. Chemiluminescence-based bidimensional immunoproteomic approach. After bi-dimensional electrophoresis of HEp-2 protein extract, we
performed immunoblotting with sera from 2 patients with autoimmune diseases, thereby generating 2 antigenic maps (A, serum 1 and serum 2). We
performed another immunoblotting (landmark map, B) using commercially available monoclonal antibodies against ACTB, HSP71, ENOA, G3P and TPIS.
This landmark allowed anchoring to be used to superimpose both the antigenic maps (A) and the colloidal blue-stained proteomic map (C). The yellow area
highlights some of the reactivity diversity between the 2 sera. The red area highlights antigenic spots (A, serum 2) for which there are no corresponding
protein spots on the CCB gel (C). Sizes of immunoblots/gel and molecular weight distribution are indicated, to point out the distortions between their
respective derived images. The differences between the relative mobility of HSP71 and G3P were measured at 3.6, 3.3 and 5.3 cm, respectively with serum
1, serum 2 and on CCB gel.
doi:10.1371/journal.pone.0132142.g001
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after 2D immunoblotting along with the antigenic and the landmark maps. It could then be
used as an internal standard. To illustrate this procedure, we revealed the HEp-2 protein spots
by Cy3 labeling (Fig 2A) and used the commercially available mAbs previously described and
the same serological samples (illustrative data with serum 1).The commercial mAbs, used as
anchors in the landmark map, were simultaneously revealed with a set of Alexa Fluor 647-con-
jugated secondary antibodies, associated with the Cy5 channel (Fig 2B). The antigenic map was
revealed with an HRP-conjugated anti-human antibody using chemifluorescence kit ECL
PLUS associated with the Cy2 channel (Fig 2C). This design allowed direct superimposition
(Fig 2D) of the antigenic map on the proteomic map. To illustrate the advantages of this
approach, we used a serological sample thought to contain both anti-ENOA and anti-G3P Abs
as suggested by SERPA (Fig 1). The FBIP procedure revealed a correct co-alignment of the
antigenic-, anchor- and protein spots for ENOA (Fig 2E). It revealed one mismatch between
Fig 2. Fluorescence-based bidimensional immunoproteomic (FBIP) approach. In the FBIP procedure, 3 maps are generated from one 2D immunoblot
(A–C). After 2-D electrophoresis of Cy3 labeled proteins (A), the immunoblotting is treated at the same time with a pool of commercially specific antibodies
(landmark) and with human serum (antigenic map). The landmark is revealed with a set of Alexa Fluor 647-conjugated secondary antibodies (B). The
antigenic map obtained with serum 1 is revealed with a horseradish peroxidase-conjugated anti-human antibody using chemifluorescence kit ECL PLUS (C).
The direct superimposition of the 3 maps in the 3 wavelengths (D) revealed correct matching of reactivity towards ENOA (E) and a mismatch for reactivity
against G3P (F). A defect of the superimposition was observed between the Cy3-labeled G3P protein and the corresponding mAb reactivity. The
reproducibility of this approach is illustrated in the S2 Fig.
doi:10.1371/journal.pone.0132142.g002
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the antigenic and the anchors spots for G3P, suggesting a wrong association between the sero-
logical reactivity and the antigenic target by SERPA (Fig 2F).
Moreover we observed an absence of superimposition of the landmark- and the protein
spots for G3P, suggesting a shift in molecular mass of Cy3 labeled proteins in the proteomic
map (Fig 2F).
Evidence of a Molecular Weight Shift Linked to the Cy3 Protein Labeling
To illustrate the molecular weight shift between the 95% of non-labeled and the 5% of Cy3
labeled protein fractions, we performed a reversible DP staining of the protein map on the
immunoblot (Fig 3A). This procedure revealed a heterogeneous shift, linked to the weak
molecular weight of labeled protein (Fig 3B) or not (Fig 3C and 3D). Moreover, we observed
that some proteins were labeled by Cy3 dye but not by DP, whereas other were labeled by DP
but not Cy3 (Fig 3E).
Correctives for Analysis of FBIP Immunoblots
The analysis of FBIP immunoblots was supported by Progenesis SameSpots software initially
designed for 2D-DIGE experiments. Using the Cy3-labeled proteomic map, considered as the
internal standard, Progenesis SameSpots software suggested a panel of correcting vectors
allowing the superimposition of all proteomic maps in order to take into account the potential
Fig 3. Assessment of heterogeneousmolecular weight shift of proteins revealed by deep purple (DP) staining. The proteomic map has been labeled
by Cy3 (green) and stained DP (red) (A). This process revealed a predominant shift of low molecular weight proteins, with the Cy3-labeled proteins appearing
heavier than the DP-stained proteins (B). The shift seemed weaker and could even disappear in the case of higher molecular weight proteins (C) but this
observation did not apply to all high MW proteins (D). Moreover, some proteins were stained only by Cy3 and others only by DP (arrows in E).
doi:10.1371/journal.pone.0132142.g003
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migration defects (Fig 4A). Using these suggested correcting vectors defined in the Cy3 chan-
nel, the same parameters were automatically applied for the superimposition of the related
landmark and antigenic maps, in the Cy5 and the Cy2 channels, respectively. In an ultimate
step, the co-alignment of the anchors of the landmark maps on the expected protein spots was
used as a final validation of the superimposition. The superimposition between the different
maps was confirmed when the designated area delineating the protein spots strictly contained
the landmark ones (Fig 4B1).
The FBIP immunoblot coupled with the Progenesis SameSpots analysis was used to
analyze the reactivities of the same two sera previously studied by SERPA. This procedure
Fig 4. Progenesis SameSpots assisted analysis of FBIP approach. For the analysis of the immunoblots, Progenesis SameSpots software begins by
inter-gel alignment step (A). To rectify the defect of superimposition of the proteomic maps revealed on each immunoblot (A1), Progenesis SameSpots
suggested correcting vectors (blue vectors in A2). This automatic alignment was improved by applying manual vectors (red vectors in A2) to obtain perfect
spot alignment (A3). For the analysis of immune reactivity, Progenesis SameSpots software displays both 2D and 3D images of reactivity associated with
protein spots (B). The verification of the co-alignment of all the landmark maps between all the studied gels, and also on the DP stained proteomic map (i.e.
HSP71 in B1) is the first step of analysis. Applied to the analysis of the reactivity of the 2 sera from patients with autoimmune diseases, this procedure
demonstrated the co-alignment of antigenic, anchor and proteomic spots identified as ENOA by MS/MS (blue circles in B2), thus confirming that these
patients had anti-ENOA autoantibodies. Using this procedure to analyze the anti-G3P (blue circles in B3) reactivity of the same 2 sera, we confirmed the data
of SERPA for serum 2, which had anti-G3P autoantibodies. For serum 1, whereas SERPA had suggested a strong reactivity against G3P, FBIP approach
revealed a weak reactivity against this target (blue circles in B3), but strong reactivity against smaller protein targets neighboring the G3P (red circles in B3),
highlighting a clear mismatch of the SERPA procedure. Additional samples analyzed with the same procedures demonstrate the robustness of the FBIP
approach (S3 Fig).
doi:10.1371/journal.pone.0132142.g004
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demonstrated that co-reactivities were shared by the two sera. As previously described with
SERPA (Fig 1), we observed a co-alignment with the anti-ENOA anchor (Fig 4B2) that was
identified by MS/MS (Table 1). For serum 2, FBIP analysis also confirmed the G3P autoreactiv-
ity previously observed with SERPA. By contrast, as expected for serum 1, the previously
observed mismatch (Fig 2F) was highlighted after Progenesis SameSpots analysis (Fig 4B3).
Even though FBIP approach revealed a weak anti-G3P reactivity for serum 1, it was not consis-
tent with the reactivity observed with SERPA, which matched with antigenic spots of lower
molecular weights identified as hnRNPs by MS/MS (Table 1).
Discussion
We have described here a co-detection system based on a fluorescent bi-dimensional immuno-
proteomic approach which allowed the exact location of protein that supported the specific
reactivities of interest. This procedure is derived from 2D-DIGE using CyDye-labeled protein
maps, which is repeated on each 2D immunoblot as internal standard. This procedure, which
includes both landmark and antigenic maps, respectively revealed by an Alexa Fluor coupled
secondary Ab and chemifluorescence, allows simultaneous visualization of the three maps:
proteomic, landmark and antigenic. It offers the guarantee of strictly superimposing antigenic
spots on the protein map if the potential molecular shift induced by the CyDye labeling is con-
sidered with complementary staining using DP. This FBIP approach is thought to improve the
classical serological proteomic approach.
SERPA has been extensively used in different scientific and medical fields, and especially for
identifying new biomarkers in cancerology [7,8], allergology [2], autoimmunity [3–6,11] and
vaccination strategy [12,15,16]. SERPA has led to the identification of targets described as bio-
markers in diseases. However, some specific biomarkers could be shared by different and unre-
lated pathological processes, as observed with proteomics [19]. These data raise questions
Table 1. List of proteins identified by LTQ-ORBITRAP-Velos.
Spot
numbera
Accession numberb Protein nameb Gene nameb pIc
Theo
pIc
Exp
MW
(kDa)c
Theo
MW
(kDa)c
Exp
Number of
identiﬁed
peptides
Total
Ion
Score
Sequence
coverage
(%)
1 P06733 ENOA_HUMAN Alpha-enolase ENO1 7 6.8 47 47 23 1392 69
2 P06733 ENOA_HUMAN Alpha-enolase ENO1 7 7 47 47 24 8133 71
3 P04406 G3P_HUMAN Glyceraldehyde-
3-phosphate
dehydrogenase
GAPDH 8.6 8.5 36 35 13 4152 54
4 P04406 G3P_HUMAN Glyceraldehyde-
3-phosphate
dehydrogenase
GAPDH 8.6 8.7 36 35 15 5692 55
5 P22626 ROA2_HUMAN Heterogeneous
nuclear
ribonucleoproteins
A2/B1
HNRNPA2B1 9 8.5 37 33 13 3157 44
6 P22626 ROA2_HUMAN Heterogeneous
nuclear
ribonucleoproteins
A2/B1
HNRNPA2B1 9 8.7 37 33 13 4122 44
aSpot number according in Fig 4B2 and 4B3.
bAccession number and protein name according SwissProt.
cIsoelectric point (pI) and molecular weight (MW): Theoretical (Theo) and Experimental (Exp).
doi:10.1371/journal.pone.0132142.t001
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about their relevance and may well explain the reduction in the number of reports published in
recent years.
Based on our experience, we hypothesized that the identification of such common reactivi-
ties could be attributed, at least in part, to a critical step of the methodological approach: the
superimposition of the antigenic and the proteomic maps. The conventional bi-dimensional
immunoproteomic approach SERPA is based on comparative analyses of different proteomic
and antigenic maps generated by separately performed distinct 2DE gels. As each of these gels
undergoes different distortion constraints, the proteomic maps are stochastically distorted.
The challenge of operator-dependent visual superimposition of the antigenic and proteomic
maps is associated with the comparison of very different kinds of images whereas few as
50 antigenic spots may have to be matched on a proteomic map containing at least 1,500 pro-
tein spots. Moreover, the distortion constraints associated with the antigenic map are largely
underestimated in relation to the few antigenic spots revealed. Together, these two methodo-
logical aspects, intrinsic to SERPA, could lead to mismatches and finally to wrong protein
identification.
Although these methodological aspects have not been clearly described yet, different strate-
gies have been employed to try to circumvent these problems. From 2004, we used commer-
cially available antibodies directed against housekeeping proteins to generate a landmark map,
containing anchors which facilitate the alignment of antigenic and protein spots [4]. This pro-
cess was adopted by Farinazzo et al. and Goeb et al. [58,59]. However, the restricted number of
spots generated and the manual stage of matching limited the correction efficiency of this
approach. Several authors have reported post-staining of the membrane, using colloidal gold
particles [34,37,53], silver [54,60] or CCB [55,61] after immunodetection. This approach pre-
sented the advantage of staining the proteomic map from each immunoblot, but it implied the
treatment of different images generated from 2 distinct steps. For example, in the procedure
applied by Canelle et al. [34], the antigenic map image was superimposed on its related colloi-
dal gold-stained transferred protein map image. Then, the stained transferred protein map
image was superimposed on the CCB-stained protein map image using Image Master 2D Plati-
nium 5 software. The alignment of spots from the transferred protein map on the CCB-stained
protein map allowed corrections of distortions between membrane and gels, making it easier to
match the antigenic and protein spots. However, this supplementary step did not eliminate
manual superimposition of the antigenic and transferred proteomic maps. Moreover, the sensi-
tivity of these stains was intrinsically lower than that of the antibody detection system, leading
to some matching defects between the antigenic and the transferred proteomic maps.
Some authors replaced post-immunostaining with fluorescent staining just after the transfer
step [62], while others added the revelation of the immunoblots by chemifluorescence [63,64].
These approaches took advantage of using the same revelation system for the post-transferred
protein and antigenic maps. But the superimposition of these 2 maps remained a manual pro-
cedure even if they used image analysis software (Adobe Photoshop) [63,64]. Some authors
have also suggested adding a ‘pen’ landmark to facilitate the superimposition of the antigenic
map on its related stained transferred protein map image [61]. The defect common to all these
approaches was the generation of multiple images that had to be aligned manually. In the
immunoblot 2D procedure, the use of fluorescent probes has previously been reported in dif-
ferent medical fields. Some authors used chemifluorescence to reveal the antigenic map
[55,63,64]. By contrast, others have used fluorescent probes for protein labeling before the elec-
trophoresis steps [65–67]. Goeb et al. [59] use a fluorescent dye for staining a landmark map in
order to confirm the localization of antigenic spots as potential autoimmune targets. In all
these works, the superimposition step remains visual.
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We describe here a one-step procedure that generates 3 images intrinsically matched by
scanning the same immunoblots with 3 different wavelengths. The manual alignment between
the antigenic and the proteomic maps is bypassed by this procedure. Moreover, proteomic
analysis software, using correcting vectors, automatically performed the alignment of all the
labeled protein maps, thereby ensuring inter-gel matching. The alignment parameters of the
protein maps are directly reported onto their related antigenic maps, thus ensuring the match-
ing of the different immunoblots.
This procedure is derived from the 2D-DIGE technology, which automatically aligns differ-
ent proteomic maps revealed at the same time using fluorescent probes read at different wave-
lengths. This approach uses an internal standard in order to match and normalize the protein
profiles. A similar approach was used in a recently published study [68]. In our study we took
advantage of the internal standard and transposed it as a repeated proteomic map on each
immunoblot in order to guarantee the matching of the antigenic maps. In our FBIP procedure,
we performed Cy3 labeling for the proteomic map associated to each immunoblot. However,
we used fluorescent revelation systems with wavelengths similar to CyDye 2 and CyDye 5 for
the antigenic and landmark maps, respectively. Moreover, using a landmark map based on an
Ab detection system, our procedure reached the sensitivity scale of the antigenic map, thus pro-
viding the means to control the quality of the alignment parameters.
Some studies have applied multiplex fluorescent probes in 2D immunoblots in order to
superimpose antigenic and proteomic maps [41,66,69]. In these studies, the proteomic map
was labeled by CyDye when the antigenic map was revealed by other fluorescent probes. Suzuki
et al. [41] and Katsumata et al. [69] performed post-blotting staining using CyDye monoreac-
tive Dye pack. This staining presents the advantage of labeling membrane-fixed proteins, but
in our experience this monoreactive dye is less sensitive than free CyDye and frequently
induces a high background that could disturb the matching of antigenic and proteomic maps.
In their procedure, Fontaine et al. [66] used 150μg of labeled proteins as antigenic sample to
detect serological reactivities during sample preparation. In our experience, to reveal such reac-
tivities on cellular or tissue extracts, 500μg of protein have to be loaded on gel as suggested by
manufacturers (GE Healthcare) to perform “preparative 2D-DIGE gels”. Such a quantity opti-
mized the revelation of immune reactivities whatever the affinity of Ab. In the experimental
conditions, of “preparative 2D-DIGE gels”, manufacturers advise the optimal labeling of a frac-
tion of protein sample to avoid too high a brightness and to enhance the resolutive separation
of signals. In this context, we observed the well-known mass shift between the free labeled pro-
teins and the CyDye stained ones. Whereas CyDye labeling was initially described as mainly
affecting the low molecular weight proteins, we observed a more heterogeneous distortion of
apparent molecular weight, likely related to the lysine distribution in the amino acid sequence
of proteins. This mass shift was recently observed in another study using a similar labeling
design [68]. However, the restricted focusing on a single antigenic target could not be expected
to resolve this question. In a large immunoscreening approach and in order to circumvent this
problem, we suggested introducing a reversible post-labeling of blotted proteins with DP
staining.
This step was crucial to optimize the matching of antigenic and protein spots to be selected
and took advantage of the use of inter-gel alignment generated by specific software, such Pro-
genesis SameSpots (Totallab), Delta2D (Decodon GmbH, Greifswald, Germany) or Decyder
(GE Healthcare). Such electronic tools aligned all CyDye stained proteomic maps, considered
as internal standard, on both the different immunoblots and the DP stained membrane. In a
second step, the software reported all the alignment correcting vectors on the antigenic maps,
allowing their superimposition on the DP map. The alignment procedure of FBIP approach
was totally operator free and could reveal mismatches of the SERPA alignment procedure
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partially based on the morphological aspects of antigenic and protein spots. This is illustrated
in our data by the mismatch on anti-G3P reactivity and hnRNP spot protein.
If the analysis of 2D immunoblots is largely assisted by 2D-DIGE derived software, they
showed limits linked to intrinsic properties of FBIP approach, mainly the qualitative exploita-
tion of experimental data. In the 2D-DIGE procedure, the interpretation of data is based on the
comparative expression level of every protein spot, normalized according to the internal stan-
dard. This generates a classification of data based on an expression differential, where 2D
immunoblots should identify intragroup similar antigenic patterns, which will be submitted to
intergroup variability analysis. For example, an antigenic spot recognized by several patients
could be missed by such 2D-DIGE analysis software, while these data could illustrate a signifi-
cant association of antigenic recognition specifically related to a disease condition. For FBIP
approach, the qualitative analysis of the signal would be sufficient for the definition of each
antigenic map, and the inter-assay comparison. Yet, the quantitative analysis of 2D-DIGE anal-
ysis software did not enable qualitative analysis in terms of presence or absence of antigenic
spots on 2D immunoblots.
Moreover, such software performed statistical analysis using principal component analysis,
where some other multiparametric statistical tests have to be used. Such approaches could jus-
tify exporting qualitative rough data in a spreadsheet format. Today, the software does not
currently offer this function. Finally, a hardware solution is able to reveal up to 5 different
channels of wavelengths, where the software only uses data generated by 3 wavelengths. For
example, a five-channel procedure allows the analysis of the impact of post-translational modi-
fications on protein antigenicity through a one-step method.
In summary, we have described an accurate method to circumvent interpretation biases
related to the superimposition procedure of SERPA. Applied with fractionation procedures
and the handling of IEF gels with restricted pI ranges which enhance the detection of low abun-
dance antigens and also improve the resolution of 2D gels, this methodological evolution of
FBIP analysis will improve the identification of pertinent biomarkers of diseases.
Supporting Information
S1 Appendix. Protein Identification by Mass Spectrometry (MS) and Database Searching.
(DOCX)
S1 Fig. Experimental design for an optimized Fluorecence-Based Immunoproteomic
(FBIP) approach for accurate screening of autoantibodies. Step 1: The proteins (Hep-2 cells
here) were extracted in lysis buffer (8M urea, 2M thiourea, 4% CHAPS, 50 mM DTT, anti-pro-
tease cocktail) and they were precipitated using the 2D clean-up kit. The protein concentration
was evaluated by Bradford assay. For each gel, 50 μg were labeled with 400 pmol Cydye (Cy3 or
Cy5). Before separation on two-dimensional (2-D) gels, 50 μg of labeled proteins were pooled
with 450 μg of labeled-free proteins. Step 2: Proteins were electrofocused according to their iso-
electric point (pI) along a non-linear immobilized pH gradient strip (pH 3–11NL, 18 cm long)
using the IPGphor III apparatus(GE Healthcare) for a total of 40,000 V.h. After focalization,
equilibrated strips were loaded onto homemade 8–18% gradient polyacrylamide gels and elec-
trophoresis was carried out in an Ettan Dalt six (GE Healthcare). Gels were run overnight at
12°C at a constant power of 3 watts/gel until the bromophenol blue dye front reached the bot-
tom of the gel. After 2-D electrophoresis, proteomic map labeled by CyDye can be visualized
by Typhoon 9400 scanner (GE Healthcare). Step 3: In order to compare the Ab reactivities of
(n) patients suffering from an auto-immune disease, (n) 2D gels were transferred onto nitrocel-
lulose membrane. Membranes were immunoblotted with a set of commercial monoclonal anti-
bodies (mAbs) (anti-HSP71, 1/1,500; anti-ENOA, 1/5,000; anti-ACTB, 1/750; anti-G3P, 1/750;
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anti-TPIS, 1/200,000) and simultaneously with a serum at 1:100 dilution. The commercial
mAbs (Landmark) were revealed using a donkey anti-mouse Alexa Fluor (AF) 647-conjugated
antibody. The patients Ab reactivities (here IgG) were revealed with a horseradish peroxidase
(HRP)-conjugated antibody and an enhanced chemifluorescence kit (ECL plus). The 3 maps
(proteomic, landmark and IgG reactivities maps) of each immunoblotted membrane were
revealed in the same time on a Typhoon 9400 scanner using 3 coupled excitation and emission
wavelengths: 532/580, 633/670, 488/520 respectively at 200 μm resolution. Step 4: To take into
account the potential MW shift related to the dye labeling, one gel was transferred onto nitro-
cellulose membrane. This membrane was stained with Deep Purple (DP) and the two proteo-
mic maps (one labeling by Cydye and the total proteomic map revealed by DP staining) were
revealed at the same time on a Typhoon 9400 scanner using two coupled excitation and emis-
sion wavelengths: 633/670; 532/580 respectively at 200 μm resolution. Step 5: The image analy-
sis software (Progenesis SameSpots) allows to align all labeled proteomic maps (used as an
internal standard) by automatic and manual correction vectors. Finally the comparison of Ab
reactivities generates a “spot picking list” which defines protein spots of interest targeted by
patients Ab. Step 6: For protein identification to selected spots, after 2-D electrophoresis, one
gel was stained with Coomassie colloidal blue (CCB). Step 7: Protein spots of interest were
excised from CCB-gel and conserved at -20°C until digestion and identification by mass spec-
trometry.
(TIF)
S2 Fig. FBIP reproducibility.Method reproducibility has been evaluated performing different
FBIP procedures (independent IEF to SDS page steps) on several protein extracts issued from
more than 3 different HEp-2 cell cultures. Here are illustrated 3 replicates (REP-1 to REP-3) of
the FBIP procedure using the same serum. The reproducibility is estimated over to 80%.
Arrows illustrated the punctual difference classically observed on antigenic maps but also on
landmark maps.
(TIF)
S3 Fig. Robustness of the FBIP alignment method. The capacity of analysis of the FBIP align-
ment method has been assessed through the analysis of different antigenic maps generated
with large cohorts of patients. The association of automatic and manual correction vectors in
combination with the verification step of the co-alignment of all the landmark maps focus the
analysis of antigenic map on specific areas, independently of the presence of reactivity. Here
are illustrated the referent DP stained proteomic map (A) and the anti ENO-A reactivity of 8
healthy subjects generated after Progenesis SameSpots analysis (B).
(TIF)
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